The pharma licensing agreement provides an opportunity for R-Pharm to conduct late-stage clinical trials in Russia, which is among the goals of the Russian government’s Pharma 2020 initiative.
Under the terms of this pharma licensing agreement, R-Pharm gains rights to develop and commercialize narlaprevir in Russia and the Commonwealth of Independent States.
R-Pharm will pay Merck an upfront payment and undisclosed royalties on sales of narlaprevir.
Merck has retained the right to co-promote narlaprevir in these regions and retains rights to the drug outside of Russia and the CIS countries.
Narlaprevir is a second generation NS3 serine protease inhibitor developed by Merck.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Hepatitis Partnering
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity